Revenue from operations rose 8% YoY to Rs 12,959 crore, up from Rs 11,983 crore in Q4FY24. However, on a sequential basis, both profit and revenue were down. PAT declined 26% from Rs 2,913 crore reported in Q3FY25, while revenue fell 5% from Rs 13,675 crore in the previous quarter.
Also Read: Adani vs Pakistan: One Indian company bigger than entire Pakistan! Harsh Goenka gives some stats
For the full financial year, net profit stood at Rs 10,965 crore versus Rs 9,610 crore in Q4FY24. Meanwhile, the revenue expanded by 8.5% to Rs 52,578 crore in Q4FY25 versus Rs 48,497 crore in the quarter ago.The company reported exceptional items worth Rs 678 crore along with an exceptional tax expense of Rs 377 crore for the year ended March 31, 2025. This includes a charge of $37.44 million (Rs 316 crore), including legal expenses of $0.7 million ( Rs 5.82 crore) in the quarter ended December 31, 2024, on the agreement of a settlement in principle on the primary financial terms, with no admission of wrongdoing in the US.
The company reported expenses of Rs 9,956 crore in the quarter under review, which was 10,349 crore in Q3FY25 and Rs 9,672 crore in the year ago period. The expenses were incurred under the heads like cost of materials consumed, purchases of stock-in-trade, employee benefit expenses and finance cost.
Also Read: RIL, SBI among 10 stocks with more than 32 buy calls
Sun Pharma shares closed at Rs 1,720 on Thursday, down 0.7% on the BSE, even as the Sensex gained 0.79%. The stock has declined 9% year-to-date but gained 84% over the last two years. Its current market capitalisation stands at Rs 4,12,675 crore.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
